Synairgen Collaboration Progress
Release Date: 23/03/2016 8:40am
Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to report progress from its ongoing collaboration with UK biotechnology company Synairgen plc (LSE: SNG) to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
Overnight Synairgen announced data generated in an in vitro model of IPF using lung cells from IPF patients, developed in collaboration with scientists at the University of Southampton. The data shows that the Pharmaxis enzyme inhibitors, by inhibiting LOXL2, are able to reduce cross-linking of collagen fibres essential for the stabilization of fibrotic tissue.
Categories: News and Media